SARCOMA DE KAPOSI CLÁSSICO, A PROPÓSITO DE UM CASO CLÍNICO | KAPOSI’S SARCOMA, CASE REPORT

Jandir Patrocínio, Ana Rita Espírito Santo, Jemima Patrocínio, Rui Pereira, Fernando Gomes, Fernanda Louro

Resumo


RESUMO
O Sarcoma de Kaposi (SK) é um distúrbio angioproliferativo descrito como doença benigna de pessoas idosas. Divide-
se em 4 tipos: O Clássico, epidémico, endêmico e iatrogénico. Os autores descrevem o caso de um homem caucasiano de
50 anos, português, que iniciou a sintomatologia 6 anos antes do internamento com lesões urticariformes na perna direita
e perda ponderal de 10 kg em 6 meses. Por agravamento das lesões e aparecimento de púrpura nos membros inferiores
recorreu ao hospital. O exame objetivo era normal à exceção de púrpuras dispersas com relevo, descamativas e violáceas na
região plantar e restante membros inferiores, membros superiores e tronco. As serologias para o HIV 1 e 2 foram negativas
a serologia viral para o Herpes virus humano 8 IGG foi positivo, PCR H8 positivo, a biópsia das lesões com histologia foi
compatível com Sarcoma de Kaposi. Iniciou o 1º ciclo de Doxorrubicina lipossómica peguilhada e manteve seguimento em
Hospital dia de Oncologia.

Palavras-chave: Sarcoma de Kaposi; Vírus herpes humano do tipo 8


ABSTRACT
Kaposi’s Sarcoma (KS) is a vascular disorders proliferative described as a benign disease of the elderly. It is divided into 4 types: The
Classic, epidemic, endemic and iatrogenic. The authors describe the case of a Caucasian male 50 years, Portuguese, who began the symptoms
six years before admission with urticarial lesions in the right leg and weight loss of 10 kg in 6 months. By aggravation of injuries and purple
appearance in the lower limbs turned to the Hospital. The physical examination was normal except for scattered embossed purple, scaly and
purplish in the plantar region and rest of the lower limbs, upper limbs and trunk. Serology for HIV 1 and 2 was negative, viral serology
human herpes virus 8 IgG was positive, PCR H8 positive, biopsy histology of lesions compatible with Kaposi’s sarcoma. Initiated the 1st
Doxorubicin liposomal cycle and kept following in Oncology Day hospital.

Keywords: Kaposi sarcoma; Human herpesvirus 8


Texto Completo:

PDF

Referências


Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, et al. Acomparison of regimens based on non-nucleoside reverse transcriptase

inhibitors or protease inhibitors in preventing Kaposi’s sarcoma. AIDS. 2003; 17:F17-22.

Krown S, Singt J. Classic Kaposi’s sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis. Uptodate 2012, version 2.0.

Stiller CA, Trama A, Brewster DH, Verne J, Bouchardy C, Navarro C, et al. Descriptive epidemiology of Kaposi sarcoma in Europe. Report

from the RARECARE project. Cancer Epidemiology. 2014; 38:670– 678.

Aka PV, Kemp TJ, Charles SR, Meredith SS, Mark NP, Carmela L, et al. A Multiplex Panel of Plasma Markers of Immunity and Inflammation

in Classical Kaposi Sarcoma. Journal of Infectious diseases. Brief Report. 2015; 9:211-226.

Krown S, Singt J. Classic Kaposi’s sarcoma: Clinical features, staging, diagnosis, and treatment. Uptodate 2012, topic 7729, version 7.0

Aldenhoven M, Barlo NP, Sanders CJ. Therapeutic strategies for epidemic Kaposi’s sarcoma. Int J STD AIDS. 2006; 17:571-578.

Wiener HW, Zhang K, Kaslow RA, Ogwaro KM, Shrestha S, Jacobson LP. A candidate gene approach for virally induced cancer with application

to HIV-related Kaposi’s sarcoma. Int J Cancer. 2014; 134(2): 397- 404

Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated

Kaposi’s sarcoma. Science. 1994; 266:1865-1869.

Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, et al. A comparison of regimens based on non-nucleoside reverse transcriptase

inhibitors or protease inhibitors in preventing Kaposi’s sarcoma. AIDS. 2003; 17:F17-22.

Eugênia MDN, Maria HV, Padilha Q, Enokihara MMSS, Almeida FA, Porro AM. Fatal outcome in classic Kaposi’s sarcoma. An Bras Dermatol.

;85(3):375-379.


Apontamentos

  • Não há apontamentos.